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ABSTRACT
Pain, and particularly chronic pain, is a difficult
outcome to measure due to its subjective and
multidimensional nature. The Institute of
Medicine estimates that 100 million Americans
have chronic pain with a cost exceeding half a
trillion dollars per year. There is a pressing need
to identify appropriate outcome measures to
better select and evaluate treatment modalities
for these patients. It is also important that we
demonstrate an evidence basis for these
decisions given the current practice standard.
Appropriate selection and implementation of
these outcome measures can help accomplish
both goals. The purpose of this review is to
explore the difficulties and opportunities unique
to pain outcome measures. The scope of the
problem and impetus for implementation of
appropriate measures is initially discussed,
followed by requisite evaluation criteria for any
measurement instrument. The authors then
review frequently employed tools for measuring
pain outcomes ranging from univariable and
single domain scales to multidimensional
instruments. A discussion of possible behavioral
and objective measures is pursued, as well as
measures of statistical and treatment efficacy.
The article closes with a review of recent and
ongoing efforts to validate and standardize pain
outcome measures and suggests directions for
future clinical and research assessment.
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INTRODUCTION
Pain has been defined as ‘‘an unpleasant sensory
or emotional experience associated with actual
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or potential tissue damage, or described in
terms of such damage’’ by the International
Association for the Study of Pain [1]. This
definition underscores that pain is a subjective
experience; therefore, unlike other chronic
diseases, such as hypertension or
hyperlipidemia, there is no single objective
measurement to best characterize the extent of
the problem or to evaluate treatment outcomes.
Measuring a patient’s pain must correlate
objective data with the patient’s subjective
reporting to provide a comprehensive outcome
representing the pain state. The purpose of this
review is to explore the difficulties and
opportunities unique to pain outcome
measures.
Complicating the measurement of pain is
the notion that the subjective experience of
pain is often confused with nociception.
Nociception involves peripheral signals
generated by specialized receptors
(nociceptors) in response to noxious stimuli.
Pain requires a functioning central nervous
system (e.g., brain) to interpret these
nociceptive signals and produce a subjective
experience. There is often a wide variability in
how much pain a given stimulus or injury will
cause. This variability is influenced by genetics,
mood, beliefs, early life experiences with pain,
sex, ethnicity, and other factors [2].
Chronic pain is often associated with an
overall reduction in the patient’s quality of life
encompassing domains such as depression,
anxiety, impaired social and physical function,
and sleep disturbance. Moreover, there appears
to be relative independence between pain and
these coexisting stressors. Therefore, to capture
the pain experience, it is necessary to also define
and characterize these related domains.
Recognizing that pain is challenging to
accurately measure, why then must we strive
to better evaluate outcomes in pain medicine?
The Institute of Medicine estimates that 100
million Americans have chronic pain with a
cost exceeding half a trillion dollars per year [3].
Current practice relies on evidence-based
medicine to support clinical decision-making
and to convince colleagues, patients, and payers
of the most efficacious treatments. The gold
standard in medicine has been the large-scale,
randomized controlled trial. There is,
unfortunately, a dearth of these studies in
pain medicine, making it all the more
imperative to accurately and consistently
measure outcomes moving forward.
Standardization of outcome reporting will
allow for comparison and systematic review of
the studies that do exist to meet the demand for
evidence-based pain treatment and may help to
answer the most pressing questions in the field
of pain: How do we know that we have helped a
patient with chronic pain, and how do we
determine which treatment, and at what cost, is
most appropriate for a specific patient?
METHODS
As this article is intended as a current review,
pertinent citations are included for each




Any tool used to measure pain should be
appropriate for the provider and patient needs.
It is of little use to have a patient fill out
multiple forms if the provider lacks the staff or
infrastructure to use the data. This underscores
the need to allocate resources efficiently when
determining appropriate outcome measures. In
defining a standard set of outcome measures,
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the Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials (IMMPACT)
consortium granted most weight to the
following criteria [4].
(A) Reliability. The instrument should
demonstrate test–retest reliability when a
patient’s status does not change over time.
It should have inter-rater reliability if the
scale is rated by clinicians, rather than
patient self-reported, and clinicians
observing the same patient should
provide similar scores. There should be
internal reliability if the scale contains
multiple items measuring the same
domain, and the scores should correlate.
(B) Validity. The scale should measure what it
is intended to measure. The scale should
display convergent validity in that it must
agree with other similar indicators and
discriminate validity in that it must be
distinguishable from related conditions.
(C) Responsiveness. The scale must display the
ability to detect changes over time and to
distinguish between treatments. This
requisite is of particular interest for
clinical trials, wherein a treatment effect
is investigated.
(D) Appropriateness. The scale’s content
should be in keeping with the measured
outcome and relevant to the patient
population being studied. The outcome
measure must be scaled to the target
patient population so that scores do not
aggregate in a restricted area of the scale
and should be at intervals to allow
statistical flexibility.
(E) Burden. The scale should be easy to
administer, complete, and score. Desire
for additional data must be balanced with
time constraints and patient adherence.
For example, daily as opposed to return
visit assessments can yield excellent
longitudinal data but may require use of
paper diaries, which are prone to
backfilling and recall bias, or daily phone
calls, which can present an inconvenience
to the patient and require significant
staffing.
UNIVARIABLE MEASURES
Unidimensional scales measure pain as a single
quality varying only in intensity and, therefore,
report a single outcome score. These methods
are most effectively used in clinics and acute
settings to provide information about current
pain and need for rescue analgesics, such
as postoperatively. Examples include the
following.
Verbal Rating Scale
The Verbal Rating Scale (VRS) consists of a series
of categorical descriptors ordered in increasing
intensity (i.e., none, mild, moderate, and
severe). The advantages of VRS are that it is
easy to administer and report, particularly for
elderly patients [5]. Disadvantages are that it has
fewer response choices (shortened scale) and the
categorical options limit statistical analysis. It
has demonstrated ability to distinguish
treatment effect, test–retest reliability, and
convergent validity in cancer pain, analgesic
trials, and evoked pain studies [6].
Visual Analog Scale
The Visual Analog Scale (VAS) is typically a
10-cm line anchored at one end by the label ‘‘no
pain’’ and at the other end by a label of ‘‘worst
pain’’. The patient marks a point on the line to
indicate their pain level and the clinician
measures the length of the line on a 101-point
scale [7]. The advantages of VAS are that there is
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good evidence for responsiveness, validity,
test–retest reliability, and scores can be treated
as ratio data [8]. The limitations are that it can
be more time consuming than other
instruments in this class and elderly people
may have difficulty using the scale [9].
Numerical Rating Scale
The Numerical Rating Scale (NRS) is the most
frequently used univariable instrument. It
consists of a rating scale from 0 to 10, with 0
signifying ‘‘no pain’’ and 10 signifying ‘‘worst
pain’’. Patients may respond orally or by circling
the appropriate number. A similar scale with 0 to
100 is also used. The NRS minimizes patient and
provider burden during data collection and
compliance is excellent. In contrast to VAS, it
can be administered via a phone interview;
however, scores cannot be treated as ratio data.
It demonstrates sensitivity to change, test–retest
reliability, and correlates wellwithothermeasures
of pain intensity [6]. The NRS is recommended by
IMMPACT as a core domain measure for future
chronic pain clinical trials [10].
Patient Global Impression of Change
The Patient Global Impression of Change
(PGIC) represents an attempt to capture pain
improvement more broadly using a single item
measure. The patient is asked to rate their
current status compared to a previous time
point from best to worst (i.e., very much
improved, much improved, minimally
improved, same, minimally worse, much
worse, or very much worse). This scale is
applicable to many conditions and treatments
but lacks sensitivity [11]. It is recommended by
IMMPACT as a core domain measure and can be
particularly helpful in gauging the clinical
importance of changes in other measures [12].
Rescue Medication Use
While not a true pain outcome scale, rescue
analgesic medications can be used as a surrogate
for pain, particularly when use is triggered by
meeting or exceeding a set pain score (i.e.,
medication X to be administered for NRS [7).
EMOTION MEASURES
There is a relationship between pain and
emotional distress and there is evidence of
relative independence [13]. Emotional
assessment instruments, either as part of a
broader multidimensional pain measure or as a
specialized emotion scale, can elucidate the
interplay of emotion and pain and help guide
therapy, particularly when emotional distress
is the primary concern. Most commonly,
depression, anxiety, and fear are found to
coexist and can significantly affect pain and
treatment outcomes. Measurements of
depression include the Patient-Reported
Outcomes Measurement Information System
(PROMIS) Emotional Distress–Depression
Item Bank (NIHPromis.org, Silver Spring,
Maryland, USA) [14], Beck Depression
Inventory (BDI) [15], Zung Self-Rating
Depression Scale [16], and Hamilton Rating
Scale for Depression [17]. Anxiety and fear
measures include the PROMIS Emotional
Distress–Anxiety Item Bank [14], Pain
Anxiety Symptoms Scale [18], State-Trait
Anxiety Inventory [19], and Fear-Avoidance
Beliefs Questionnaire (FABQ) [20]. Of these,
the BDI has been most extensively studied,
demonstrating internal consistency (Cronbach
alpha 0.73–0.95), test–retest reliability
(Pearson’s r 0.80–0.90), and convergent
validity (Pearson r mean = 0.60), leading it to
be recommended by IMMPACT as a core
outcome for Health-Related Quality of Life
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(HRQoL) as part of future clinical trials in
treatments of chronic pain [10].
MULTIDIMENSIONAL MEASURES
Chronic pain requires a more comprehensive
assessment than a univariable or single domain
measure can provide. This assessment should
include reports of several dimensions of pain
(quality, intensity, location), disability,
emotional affect, and effect on quality of life.
This complex approach to the pain experience
is much more likely to reflect the impact of pain
on a patient’s life. Commonly used scales
include the following.
Brief Pain Inventory
The Brief Pain Inventory (BPI) was developed by
the Pain Research Group of the World Health
Organization (WHO) Collaborating Centre for
Symptom Evaluation in Cancer Care to measure
both the sensory dimension of pain (intensity)
and the reactive dimension (interference in
patient’s life) [21]. The BPI has been used
mostly for cancer pain and consists of a
17-item scale that typically takes under 15 min
to complete. It has been validated in multiple
languages and demonstrates good sensitivity to
pharmacologic treatment effects. The BPI
interference scale, in particular, has been
validated as a measure of physical functioning
in multiple domains and is recommended by
IMMPACT as a core HRQoL measure [10].
McGill Pain Questionnaire
The McGill Pain Questionnaire (MPQ) was
developed to specify the qualities of pain [22].
Pain is scaled in three dimensions (sensory,
affective, and evaluative) and the questionnaire
consists of 20 sets of words for each dimension
with each having from two to six descriptors
that vary in intensity. Multiple studies have
supported the reliability and validity of the
MPQ for specific pain syndromes [23] and it is
available in multiple languages. It takes
approximately 15 min to complete. The Short-
Form McGill Pain Questionnaire (SF-MPQ) was
developed for research purposes and consists of
15 words from the sensory and affective
categories from the standard long form with a
four-point rating scale for each, a pain intensity
VAS score, and overall assessment of pain VRS
score [24].
West Haven-Yale Multidimensional Pain
Inventory
The West Haven-Yale Multidimensional Pain
Inventory (WHYMPI) best assesses adaptation
to chronic pain [25]. It can yield clinically
useful information regarding pain-coping
styles, such as adaptive copers, interpersonally
depressed, or dysfunctional copers. It is
composed of 52 items with 12 subscales,
including perceived interference of pain,
response from significant others, pain
intensity, emotional affect, perceived control,
and participation in social or work activities.
Patients respond to the questions on a seven-
point scale. The WHYMPI has been validated for
diverse pain syndromes and is sensitive to
treatment effects. The WHYMPI interference
scale correlates with physical functioning and is
recommended by IMMPACT as an alternative to
the BPI [10].
Medical Outcome Study 36-Item
Short-Form Health Survey and Treatment
Outcomes of Pain Survey
The 36-Item Short-Form Health Survey (SF-36)
is a frequently used measure of function and
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quality of life in a variety of patient populations
[26]. It consists of eight subscales, including,
physical function, limitations due to physical
problems, social function, pain, limitations due
to emotional problems, general mental health,
vitality, and general health perceptions. It takes
approximately 10 min to complete and scores
can be compared across multiple populations.
While widely used, it features only two
questions related to pain and there are
concerns about insensitivity to change when
measuring an individual patient.
The Treatment Outcomes of Pain Survey
(TOPS) is an extension of the SF-36 specifically
designed for patients with chronic pain [27, 28].
TOPS derived many of its questions from other
previously discussed measures, including the
SF-36, WHYMPI, BPI, and FABQ. It consists of
120 items with a 61-item follow-up and addresses
pain symptoms, function, perceived disability,
objective disability, satisfaction with treatment,
fear avoidance, coping, life control, limitations,
demographics, and substance abuse history. The
scale scores are quite comprehensive, and have
been found sensitive to change and have good




Pain instruments used with children or patients
with significant impairment must be
compatible with cognitive abilities. The
patient should be able to meaningfully
interpret the scale and understand its
intervals, and this ability must be assured
before using the scales. Achieving this goal can
often be achieved through modification of adult
scales. The Colored Analog Scale (CAS) replaces
a VAS with gradually increasing red coloring to
indicate increasing intensity of pain, whereas
the Wong-Baker FACESTM Pain Rating Scale
(Wong-Baker Foundation, Oklahoma City, OK,
USA) replaces a VAS with varying facial
expressions from crying to smiling. A major
disadvantage of these scales, however, is
difficulty separating pain from other sources of
sadness, anxiety, or anger.
For nonverbal adults or infants when self-
report is not possible, several tools have been
proposed to evaluate facial or body movements
as proxies for pain [29, 30]. While these
measures may be necessary clinically, they are
unlikely to meet the scientific standard for
reporting.
OBJECTIVE MEASURES
Several physiologic variables have been
suggested as surrogates for pain, including
autonomic activity, such as skin conductance
[31] and heart rate [32] or biomarkers of pain
intensity [33]. Caution with interpreting these
peripheral measures is urged as they can be
influenced by many forms of arousal other than
pain and can be modulated by nonanalgesic
medications. Physical function tests, such as
range of motion and strength, have been used
as proxies for pain, including the timed ‘‘Up and
Go’’ test for osteoarthritis [34], loaded forward-
reach test for low back pain [35], and grip
strength for rheumatoid arthritis [36]; however,
these only modestly predict self-reported pain
scores, suggesting that other factors heavily
influence the subjective experience of pain.
More recently, attempts to objectively measure
pain have focused on the brain using a
neuroimaging approach. Indeed, recent studies
suggest that brain imaging can be used to
objectively distinguish the presence of evoked
painful stimuli [37] as well as the presence of
chronic low back pain [38]. Despite these
promising early reports using neuroimaging as
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an objective biomarker of pain, there is still
much research to be done to validate its use.
Furthermore, given the expense and time
involved it is more likely that neuroimaging
will primarily be used to help guide further
research and understanding of brain
mechanisms involved in pain—at least for the
foreseeable future. All of these data further
emphasize the complex interplay between
sensory, cognitive, and affective components
of pain, and reinforces the message that it is
unlikely that an objective clinical measure for
pain will soon emerge for daily use.
CLINICAL TRIALS AND OUTCOMES
DATA
In addition to the clinical need to provide and
document appropriate care for pain, there is
clearly an impetus to provide the evidence
necessary to guide and justify appropriate
treatments. This has resulted in efforts
involving academia, pharmaceuticals, and
government agencies to define and standardize
outcome measures, both for pain and similar
related disease states. IMMPACT defined six
core outcome domains that should be
considered when designing clinical trials,
including pain, physical functioning,
emotional functioning, participant ratings of
improvement, symptoms and adverse events,
and participant disposition [39]. IMMPACT
went on to define specific validated measures
for each of the core outcome domains in the
follow-up IMMPACT-II, including NRS, use of
rescue analgesics, WHYMPI interference scale,
BPI interference items, BDI, Profile of Mood
States, PGIC, passive capture of adverse events,
participant disposition, and tailored measures
specific to the study population [4].
The National Institutes of Health recently
funded PROMIS with the goal of developing
valid, reliable, and standardized questionnaires
to measure patient-reported outcomes. These
assessment instruments were developed
between 2004 and 2009 to yield calibrated
item banks measuring domains, such as pain,
fatigue, physical function, depression, anxiety,
and social function. These banks can be used to
produce short forms or computerized adaptive
tests for researcher and clinician use, and are
available at http://www.assessmentcenter.net [14].
The second phase of PROMIS is ongoing and
focuses on the development of new tools to
measure patient-reported outcomes (PROs) and
validation of the current item banks.
CLINICAL VERSUS STATISTICAL
SIGNIFICANCE
Outcome measures for pain provide a metric by
which treatments and progression can be
compared. Ideally, an effective intervention
should demonstrate both a clinically and
statistically significant difference versus
alternative treatment or placebo. However, they
are not always linked. For example, as sample size
increases, statistical significance increases
regardless of clinical effect. Thus, to interpret
the results of a clinical trial, the clinically
relevant effect size must first be determined.
Studies suggest that for pain, a 30% reduction,
corresponding with a PGIC of ‘‘much improved’’
or ‘‘very much improved’’, two-point reduction
on NRS [12, 40], or 35-mm reduction on VAS
represents a satisfactory result for the patient
[41]. The most recent IMMPACT consensus
statement addresses clinical importance of
outcomes and advocates the use at least two
measures from different core domains with the
inclusion of at least one ‘‘anchor’’-based measure
to relate changes in scores to a standard that
differs from the measure itself (for example,
relating NRS scores to PGIC) [10].
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DISCUSSION
The assessment of pain remains a challenge but
the landscape is improving in development and
adoption of appropriate outcome measures.
Most clinicians and researchers recognize that
chronic pain is a multidimensional experience
requiring appropriate attention to sensory,
emotional, functional, and cognitive aspects in
addition to the univariable pain intensity scores
frequently used in the acute setting. Given the
multitude of instruments available to assess
pain outcomes, deciding upon a specific tool
for any given situation can be difficult. Indeed,
a recent systematic review of pain outcomes in
chronic low back pain demonstrated 75
different outcome measures cited to evaluate
therapy, and the reader is referred to this article
for a more in-depth discussion of the validity,
reliability, and responsiveness of each in this
context [42]. In summary, the authors of the
study recommend use of the VAS or NRS for
pain responsiveness, the Oswestry Disability
Index or Roland Morris Disability index for
physical functioning, and the SF-36 for quality
of life measures. Regardless of the measures
chosen, each scale represents a compromise
between factors of sensitivity and specificity,
comprehensiveness and burden. It can be
tempting to administer a barrage of measures
but this approach can significantly increase the
burden on both patient and staff, and lead to
decreased compliance. The key to choosing an
instrument is to be sure that it measures the
appropriate domain of interest and to balance
the quality and quantity of information.
The results of IMMPACT and PROMIS have
suggested core outcome domains, validated
measures, and item banks that can be easily
accessed by researchers and clinicians alike. In
addition, specific pain conditions may require
tailored measurements for that population and
outcome. For example, the study of acute post-
surgical pain may focus on intensity of pain and
need for rescue analgesics, while chronic pain
conditions are more likely to require
multidimensional assessment. Use of
standardized outcomes and measurements,
and making these readily accessible to
providers and patients, holds significant
promise to ensure the best delivery of care and
the advancement of pain medicine.
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